Modality
Multispecific
MOA
PD-1i
Target
MDM2
Pathway
Epigenetic
MG
Development Pipeline
Preclinical
~Nov 2012
→ ~Feb 2014
Phase 1
~May 2014
→ ~Aug 2015
Phase 2
~Nov 2015
→ ~Feb 2017
Phase 3
May 2017
→ Mar 2030
Phase 3Current
NCT07112776
1,927 pts·MG
2018-11→2025-12·Not yet recruiting
NCT08278660
1,515 pts·MG
2023-11→2030-03·Recruiting
NCT07720349
2,671 pts·MG
2019-07→2025-10·Completed
+1 more trial
7,541 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-10-185mo agoPh3 Readout· MG
2025-12-283mo agoPh3 Readout· MG
2028-01-031.8y awayPh3 Readout· MG
2030-03-224.0y awayPh3 Readout· MG
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P3
Active
P3
Not yet…
P3
Complet…
P3
Recruit…
Catalysts
Ph3 Readout
2025-10-18 · 5mo ago
MG
Ph3 Readout
2025-12-28 · 3mo ago
MG
Ph3 Readout
2028-01-03 · 1.8y away
MG
Ph3 Readout
2030-03-22 · 4.0y away
MG
RecruitingActiveCompletedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07112776 | Phase 3 | MG | Not yet recr... | 1927 | EDSS |
| NCT08278660 | Phase 3 | MG | Recruiting | 1515 | BodyWt |
| NCT07720349 | Phase 3 | MG | Completed | 2671 | PASI75 |
| NCT05087884 | Phase 3 | MG | Active | 1428 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R | |
| ITO-535 | iTeos | NDA/BLA | MDM2 | |
| ALM-8546 | Alumis | Phase 1/2 | MDM2 |